CN103751739B - The Chinese medicine composition for the treatment of chronic gastritis, its application in the medicine of preparation treatment chronic gastritis and preparation method thereof - Google Patents
The Chinese medicine composition for the treatment of chronic gastritis, its application in the medicine of preparation treatment chronic gastritis and preparation method thereof Download PDFInfo
- Publication number
- CN103751739B CN103751739B CN201310742427.4A CN201310742427A CN103751739B CN 103751739 B CN103751739 B CN 103751739B CN 201310742427 A CN201310742427 A CN 201310742427A CN 103751739 B CN103751739 B CN 103751739B
- Authority
- CN
- China
- Prior art keywords
- parts
- chronic gastritis
- treatment
- composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese medicine composition for the treatment of chronic gastritis, its application in the medicine of preparation treatment chronic gastritis and preparation method thereof. The weight portion composition of each bulk drug comprises: 10～20 parts of Radix Codonopsis, 5～12 parts of the bighead atractylodes rhizomes, 10～15 parts, Poria cocos, 2～8 parts, Radix Glycyrrhizae, 3～9 parts of the tuber of pinellia, 5～10 parts of cuttlebones, 9～15 parts of blood clams, 3～10 parts of the barks of official magnolia, 3～10 parts of corydalis tubers, 3～6 parts of fructus amomis, 3～10 parts of rhizoma zingiberis, 3～10 parts of the banksia rose. Can be according to pharmacy common process by described composition, add pharmaceutically conventional auxiliary material, make pharmaceutically acceptable peroral dosage form. The present invention is directed to present treatment chronic gastritis Western medicine large to human body side effect, and the shortcoming of easily repeatedly showing effect provides a kind of instant effect for the treatment of chronic gastritis, the Chinese medicine composition that side effect is little and preparation thereof. The present invention also provides the application of this medicine in preparation chronic gastritis.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition for the treatment of chronic gastritis. The present inventionAlso the preparation method and application of Chinese medicine composition of this treatment chronic gastritis will be related to.
Background technology
Chronic gastritis is gastric mucosa chronic inflammation or the atrophic lesion being caused by different pathogeny, is mainly divided into clinically non-Atrophic gastritis (superficial gastritis), atrophic gastritis and specific type gastritis three major types, be common clinical, multipleDisease, its incidence of disease occupies first of each stomach trouble, account for and accept the more than 80%～90% of gastrocopy patient, and its incidence of disease increased with the ageGrow and raise. Chronic non-atrophic gastritis can develop into atrophic gastritis, to cancer of the stomach, and serious threat patient's life.
Doctor trained in Western medicine it is generally acknowledged chronic gastritis disease because physical, chemical property and biological adverse factor continue repeated action inSusceptible population causes gastric mucosa chronic inflammation, and wherein domestic digestion circle scholar unanimously thinks pathogenic factors and the pylorus of chronic gastritisThe factors such as pylori (Hp) infection, autoimmunity, Duodenal reflux, environmental factor, mental element, age are relevant. Wherein pylorusHelicobacter (Hp) is the main pathogenic of chronic gastritis, and helicobacter pylori increases gastric acid secretion by increasing gastrin; LongAfter phase infection, can there are Mucosal atrophy and intestines in some patients were, and research shows 80%～95% chronic active gastritis patientIn gastric mucosa, exist Hp to infect, chronic gastritis degree of inflammation infects and the proportional relation of Hp bacterium amount with having or not Hp, and eradicating Hp can makeStomach lining inflammation disappears, and chronic inflammation degree alleviates, and becomes one of key link for the treatment of chronic gastritis.
Western medical treatment is to eradicate Hp, press down acid or relieving haperacidity treatment, to strengthen gastric mucosal defense as main. Eradicate the current suggested design of HpIt is the tetrad scheme that adds 2 kinds of antibiotic compositions with bismuth agent, PPI. Press down acid or antiacid treatment according to the state of an illness or severity of symptom choosingWith antiacid, H2 receptor blocking pharmacon, proton pump inhibitor. The medicine that strengthens gastric mucosal defense has bismuth agent, aluminium carbonic acid preparation and sulphurSugar aluminium etc. Western medicine is rapid-action, and clinical remission rate is high, but easily recurrence after drug withdrawal, long-term prescription side reaction is many. And treatment by Chinese herbsThis disease has some superiority, can many target spots integrally-regulated at many levels, not only can improve the clinical symptoms of chronic gastritis, also can be totalStructural reform is apt to life quality, reduces recurrence.
Modern study shows, Patients with Chronic Gastritis is the vomiting of Recurrent Abdominal Pain abdominal distension due to Gastric mucosal lesion, impact trace unitThe absorption of element, so that Most patients microelement deficiencies, and microelement deficiencies can cause patient's appetite and immunologic functionDecline, cause chronic gastritis symptom to increase the weight of. Patients with Chronic Gastritis iron, zinc content is on the low side, can make the wound face of gastric mucosa to bacteriumRecover slow, affect cell migration, T cell quantity reduces, body opposing appeal declines, easy infection helicobacter pylori in stomachAnd cause gastritis.
In existing patent, treat the more of chronic gastritis, similar with the technology of the present invention have a following prior art:
No. 201210133609.7 patents of invention of Chinese patent disclose a kind of Chinese medicine composition for the treatment of chronic gastritis, itsIn weight portion, comprise following component: Radix Codonopsis 12-18, bighead atractylodes rhizome 9-15, Poria cocos 9-15, dried orange peel 5-7, tuber of pinellia 7-11, banksia rose 7-11, fructus amomi 2-4, monkshood 5-7, rhizoma zingiberis 5-7, Radix Glycyrrhizae 5-7. No. 200810115341.8 applications for a patent for invention of Chinese patent discloseA kind of drug regimen for the treatment of chronic gastritis and preparation method thereof, active ingredient of the present invention is by Radix Codonopsis, the bighead atractylodes rhizome, Poria cocos, whiteChinese herbaceous peony, Ligusticum wallichii, dried orange peel, fructus amomi, monkshood, rhizoma zingiberis, Radix Glycyrrhizae, the bark of official magnolia, the Radix Astragali, the membrane of a chicken's gizzard form through extracting. In above-mentioned two patent formulationsAll contain raw medicinal material monkshood, in public's general knowledge, monkshood toxicity is larger, caused by aconitine-type alkaloids, poisoning symptom mainly withNervous system, the circulatory system and digestive system show as master, aconitine is larger to cardiac toxic. Though aconitine contains after concoctingAmount reduces, but still has certain toxic and side effect, and human body is taken the potential safety hazard that rear existence is very large.
Functional dyspepsia FD (FD) be one group with glutted, belly after continuation or repeatability outbreak upper abdomen pain, foodFlatulence, belch, the clinical syndrome that early full, apocleisis, the epigastric discomfort such as feel sick are cardinal symptom. Due to functional dyspepsia FD(FD) and Patients with Chronic Gastritis all there are indigestion clinical symptoms, specificity is not strong, and diagnoses according under gastroscope, FD is with slowProperty gastritis be difficult to difference, differentiate comparatively difficulty. But both belong to two kinds of diseases clinically, research shows that both,, in the cause of disease, examineBreak and treat and all have difference. (1) cause of disease difference. Chronic gastritis becomes feature with stomach lining organic diseases, often have cause glutinousThe clear and definite cause of disease of membrane damage, wherein the overwhelming majority is helicobacter pylori infections. Helicobacter pylori, by producing ammonia, secretes cavity poisonThe mechanism such as element, cytotoxin and attraction neutrophil infiltration cause mucosal inflammation infringement. FD refers to one group of Upper abdominal pain or notSuitable clinical syndrome, often there is no the clear and definite cause of disease, and pathogenesis is, internal organ Gao Min abnormal with hydrochloric acid in gastric juice, digestive tract power oftenThe factors such as perceptual and nervous anxiety are relevant. In bibliographical information, although some patients were may exist helicobacter pylori infections and antibacterialTreatment is effective, but long-term efficacy not obvious. Show that without abundant proof Hp can cause indigestion at present. Hp in FD recall rate alsoNot obvious higher than crowd's control group, there is quite a few FD patient clinical symptom clearly, and infect without Hp; Even if Hp infectsFD patient, after radical cure Hp, chronic active gastritis pathology take a favorable turn or disappears, but its symptom is improved and is unsatisfactory. (2) diseaseChange feature difference. Though FD patient's symptom can occur repeatedly,, can't there is obvious pathology in long-term existence. No matter be shallow tableProperty gastritis, or atrophic gastritis, all have galandular epithelium pathology in various degree, and small part has the risk of canceration. (3) diagnostic methodDifferent. FD is based on symptomatic diagnosis, and prerequisite is must get rid of stomach lining whether to have organic disease; The diagnosis of FD is based on symptomDescription, emphasize dyspeptic symptom. Chronic gastritis is paid close attention to stomach lining pathology damage, with Active inflammation and galandular epithelium pathologyFor feature, the erosion that endoscopic manifestations is stomach lining, or pathological biopsy has obvious neutrophil infiltration body of gland to destroy, or atrophyVenereal disease change etc. (4) treatment emphasis difference. The therapeutic purpose of chronic gastritis is mainly the reparation prevention malignant diseases that promote stomach liningBecome or the generation of other complication, because this disease is many by helicobacter pylori infections, bring out mucous membrane neutrophil infiltration and body of glandDestroy, therefore emphasize etiological treatment, i.e. eradicate helicobacter pylori. Symptomatic treatment is emphasized in the treatment of FD, and relief of symptoms is made the life betterQuality, irrelevant with stomach lining disease damage and reparation state.
No. 201110259190.5 applications for a patent for invention of Chinese patent disclose a kind of medicine for the treatment of functional dyspepsia FDCompositions, is characterized in that, calculates by weight, and said composition is by Radix Codonopsis 15, rhizoma atractylodis macrocephalae 10, Poria cocos 10, honey-fried licorice root 5, gingerThe bark of official magnolia 10, the banksia rose 10, fructus amomi 6, stir-baked RHIZOMA CORYDALIS with vinegar 15 and rhizoma pinellinae praeparata 10 form; By regulate liver spleen can obviously improve fullness in stomach,Epigastric distending pain, food lack the symptoms such as indigestion and loss of appetite, and can improve stomach power.
Above-mentioned composition is used for the treatment of to chronic gastritis, and curative effect is as one wishes not to the utmost, as suppressed the not vertical reason of helicobacter pylori effectThink, press down sour effect and general to stomach lining repairing effect. The applicant increases by three taste flavour of a drug on the basis of above-mentioned composition, largeImprove greatly the inhibition to helicobacter pylori, to stomach lining repair with press down sour effect, and Patients with Chronic Gastritis is mendedFill trace element, improve immunity of organisms, greatly improved the effect for the treatment of chronic gastritis, safe and effective.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition for the treatment of chronic gastritis. The present invention also will relate to this controllingTreat preparation and the application of the Chinese medicine composition of chronic gastritis.
The present invention is achieved by the following technical solutions: a kind of Chinese medicine composition for the treatment of chronic gastritis, its feature existsIn, formed by following weight portion bulk drug: 10～20 parts of Radix Codonopsis, 5～12 parts of the bighead atractylodes rhizomes, 10～15 parts, Poria cocos, 2～8 parts, Radix Glycyrrhizae, half3～9 parts of summers, 5～10 parts of cuttlebones, 9～15 parts of blood clams, 3～10 parts of the barks of official magnolia, 3～10 parts of corydalis tubers, 3～6 parts of fructus amomis, dry3～10 parts of ginger, 3～10 parts of the banksia rose.
Preferred bulk drug consumption is counted by weight: 15 parts of Radix Codonopsis, 10 parts of the bighead atractylodes rhizomes, 10 parts, Poria cocos, 6 parts, Radix Glycyrrhizae, the tuber of pinellia 9Part, 10 parts of cuttlebones, 10 parts of blood clams, 10 parts of the barks of official magnolia, 10 parts of corydalis tubers, 6 parts of fructus amomis, 9 parts of rhizoma zingiberis, 10 parts of the banksia rose.
Radix Codonopsis invigorating the spleen benefit lung in side; Bighead atractylodes rhizome strengthening the spleen and replenishing qi; Poria cocos excreting dampness invigorating the spleen, the relieving haperacidity of cuttlebone hygroscopic, fructus amomi dampness elimination temperatureSpleen, in the sweet mitigation of Radix Glycyrrhizae; Corydalis tuber promoting blood circulation and stopping pain; Banksia rose promoting qi circulation and relieving pain; The dissolving phlegm of bark of official magnolia eliminating dampness, lower gas are except full; The tuber of pinellia is arduousEnter stomach, stopping nausea and vomiting by lowering the adverse flow of QI; Be aided with rhizoma zingiberis warming spleen and stomach for dispelling cold, strengthen its pungent merit of opening dissipating bind; Blood clam relieving gastric hyperacidity to alleviate stomachache; Radix Glycyrrhizae tonifying spleen benefitGas, relieving spasm to stop pain is in harmonious proportion. All medicine compatibilities, play strengthening spleen and nourishing stomach altogether, press down acid dehumidifying, and dissipate-swelling pain relieving suppresses and kills helicobacter pylori.
Modern pharmacology effect shows: in Radix Codonopsis, asiabell effective ingredient polysaccharide can strengthen the phagocytic function of reticuloendothelial systemAnd the immunity of body, improve gastric mucosal barrier and protect the effect of stomach lining. Baizhu volatile oil can strengthen reticuloendothelial systemPhagocytic function, improve lymphocyte transformation rate, promote cellular immune function, and obviously increase IgG, therefore improve immunity;Also can improve the wriggling function of stomach and intestine. Pachymaran has the effect that strengthens immunologic function. Radix Glycyrrhizae has protection stomach containing enoxoloneThe barrier action of mucous membrane, is conducive to the reparation of stomach lining. The tuber of pinellia can promote gastrointestinal peristalsis, has the gastric juice free acid of reduction and total acidDegree, suppresses pepsin activity, and protection stomach lining, promotes the effect that stomach lining is repaired. In the bark of official magnolia, magnolol has anti-inflammatory, anti-Bacterium, antiulcer effect. Corydalis tuber can reduce total acidity in stomach, promotes ulcer healing, and conditioning flatulence is improved gastrointestinal function. Fructus amomiDecocting liquid has extraordinary prevention effect to pyloric ligation ulcer. The bowel movement of banksia rose adjustable gastric, banksia rose acetone extract canSuppress rat gastric ulcer, protection stomach lining. Cuttlebone can in and hydrochloric acid, prevent hyperhydrochloria, strengthen cytoprotection. Blood clam toolThere are gastric acid inhibitory and anti-peptic ulcer effect. Can suppress gastrointestinal smooth muscle contraction, gastrointestinal peristalsis is slowed down; Can press down simultaneouslyGrowth of H. pylori processed. Rhizoma zingiberis has obvious inhibitory action to stress ulcer, can suppress gastric acidity and gastric secretion; CanSuppress growth of H. pylori.
The present invention and prior art are made up of similar prescription, but principle all has different from effect: Chinese patent201110259190.5 number application for a patent for invention discloses a kind of drug regimen for the treatment of syndrome of spleen-deficiency and QIstagnation functional dyspepsia FDThing, is characterized in that, calculate by weight, said composition by Radix Codonopsis 15, rhizoma atractylodis macrocephalae 10, Poria cocos 10, honey-fried licorice root 5, stir-baked CORTEX MAGNOLIAE OFFICINALIS with rhizoma zingiberis recens juice 10,The banksia rose 10, fructus amomi 6, stir-baked RHIZOMA CORYDALIS with vinegar 15 and rhizoma pinellinae praeparata 10 form; By regulating, liver spleen can obviously improve fullness in stomach, gastral cavilty is swollenBitterly, food lacks the symptoms such as indigestion and loss of appetite, and can improve stomach power.
Chronic gastritis and functional dyspepsia FD, in the cause of disease, all have difference in diagnosis and treatment. By aforementioned pharmaceutical compositionsBe used for the treatment of chronic gastritis, result for the treatment of exists to be queried. Above-mentioned patent drug composition be from improving fullness in stomach, gastral cavilty is swollenBitterly, the few symptom such as indigestion and loss of appetite of food, and can improve stomach power aspect treatment functional dyspepsia FD, therapeutic purpose is relief of symptoms;And the treatment of chronic gastritis need to be from promoting stomach lining reparation, the treatment of eradicate helicobacter pylori aspect, whether this pharmaceutical compositionThere is effect of this respect, need further experiment just can draw.
The present invention treats chronic gastritis composition and compares with above-mentioned patent composition, has increased by three taste medicines, is respectively extra large PiaoOctopus, blood clam and rhizoma zingiberis. This is not simple modifying a prescription, and the increase of this three tastes medicine has improved treatment chronic gastritis greatlyCurative effect.
Increasing this three tastes medicine effect is respectively: cuttlebone inducing astrigency dehumidifies and relieving haperacidity, blood clam relieving gastric hyperacidity to alleviate stomachache, and the pungent temperature of rhizoma zingiberis is looseCold, strengthen its pungent merit of opening dissipating bind. Replenish qi to invigorate the spleen in original prescription, on dissipate-swelling pain relieving basis, press down acid dehumidifying, temperatureization is loose cold. Pass throughRadix Glycyrrhizae is joined rhizoma zingiberis as medicine pair, and yang-tonifying gas is led in pungent sweet combination, eliminates be shaded or hidden for foliage. Pharmacological action shows acid inhibitor in the present compositionCuttlebone, blood clam, the tuber of pinellia, rhizoma zingiberis has the acid of pressing down, gastric acid secretion inhibiting and strengthens barrier of gastric mucosa effect, and can use promotionThe medicine of gastric emptying is to promote gastric content emptying. Cuttlebone is that neutrality presses down sour medicine, can in and hydrochloric acid in gastric juice, can obviously adsorb stomach eggWhite enzyme and in and hydrochloric acid in gastric juice. Blood clam is that neutrality presses down sour medicine, has gastric acid inhibitory and anti-peptic ulcer effect, can also press down in additionGastrointestinal smooth muscle contraction processed, slows down gastrointestinal peristalsis; Compound blood clam electuary has the work that suppresses growth of H. pyloriWith. The tuber of pinellia is modulability antisecretory, regulates the secretion of hydrochloric acid in gastric juice by various neurohumor approach, presses down sour work thereby reachWith. Rhizoma zingiberis is modulability antisecretory, can suppress gastric acidity and gastric secretion, and the use of tuber of pinellia compatibility, and inhibition is stronger;Can suppress growth of H. pylori simultaneously. The adding better gastric acid inhibitory and suppress helicobacter pylori of three taste medicines. Sea simultaneouslyThe egg capsule of a mantis and blood clam contain abundant trace element and amino acid, especially contain abundant Zn element and Fe element, improve bodyImmunity, to Green Tea Extract, contributes to the reparation of stomach lining and the improvement of symptom.
Although in prior art, recorded this three herbal medicine relieving haperacidity, press down acid function, prior art unexposed mistake:In composition, increase " cuttlebone, blood clam and rhizoma zingiberis " and can produce the effect for the treatment of chronic gastritis, for example, do not disclose increasingAdding these medicines can produce " eradicate helicobacter pylori ", " promoting stomach lining reparation and anti-inflammatory " and " improve Patients with Chronic GastritisTrace element " effect.
The present invention improves pharmaceutical composition and has an unexpected effect at tool aspect treatment chronic gastritis.
(1) eradicate helicobacter pylori:
Experimental result finds that the present composition is aspect inhibition helicobacter pylori, and effect is better than treatment
With Radix Codonopsis 15, rhizoma atractylodis macrocephalae 10, Poria cocos 10, honey-fried licorice root 5, stir-baked CORTEX MAGNOLIAE OFFICINALIS with rhizoma zingiberis recens juice 10, the banksia rose 10, fructus amomi 6, stir-baked RHIZOMA CORYDALIS with vinegar 15 and methodThe control sample composition that the tuber of pinellia 10 forms.
Reason may be, now there are some researches show, compound blood clam electuary has the effect that suppresses growth of H. pylori, itsBacteriostasis is better than cimetidine. Rhizoma zingiberis has very strong bacteriostasis to external Hp. Cuttlebone and blood clam contain abundant in additionIn the compositions such as calcium carbonate and hydrochloric acid in gastric juice, improve the pH value of gastric juice, disturbed Hp existence and bred environment, Hp is also had to certain inhibitionOr scavenging action.
(2) promote stomach lining reparation and anti-inflammatory:
Test of pesticide effectiveness result shows, medicine composite for curing of the present invention obviously subtracts Antrum, gastric body mucosa layer inflammationGently, hole, body body of gland layer obviously thicken, and show stomach lining inflammation and the stomach of the present composition to experimental chronic gastritis ratMucosal atrophy pathology has obvious therapeutic action, have the effect of renovating tummy mucous membrane damage, and effect is better than control sample group. CombineThe above, pharmaceutical composition of the present invention promotes stomach lining repair to be better than control sample composition.
The ear swelling degree of the each dosage group of the present composition is all significantly less than Normal group, shows that this medicine is to twoMouse ear acute inflammation swelling due to toluene has antiinflammatory action, and antiphlogistic effects is suitable with control sample composition.
(3) improve Patients with Chronic Gastritis trace element:
Patients with Chronic Gastritis is the vomiting of Recurrent Abdominal Pain abdominal distension due to Gastric mucosal lesion, affects micro-absorption, consequentlyMost patients microelement deficiencies, and microelement deficiencies can cause that patient's appetite and immunologic function decline, and cause chronicGastritis symptom increases the weight of. In the present composition, containing a large amount of amino acid, trace element, can improve immunity of organisms, to Green Tea Extract,Contribute to the reparation of stomach lining and the improvement of symptom.
Experiment shows, in chronic gastritis rat model blood, Fe, Zn content obviously reduce, and Cu/Zn value raises, and affects mucous membraneRepair, thereby cause helicobacter pylori infections to increase the weight of. The present composition can raise Fe, Zn in chronic gastritis rat model bloodContent, has significant difference (p < 0.05, p < 0.01); And more remarkable than control sample group effect.
(4) press down acid:
The test of pesticide effectiveness shows, model group rat gastric juice free acidity obviously reduces, and gastric juice pepsin activity obviously raises,Serum gastrin content and Plasma Motilin Levels and Colonic Motility content significantly increase, with Normal group comparing difference have statistical significance (p <0.01). After the treatment of this composition, rat gastric juice free acidity all significantly raises, and rat gastric juice pepsin activity, serum stomach are secretedCellulose content, Plasma Motilin Levels and Colonic Motility content significantly reduce. This pharmaceutical composition of result display reminding can improve the above-mentioned stomach of rat modelThe ANOMALOUS VARIATIONS degree of liquid composition and serum gastrin and Plasma Motilin Levels and Colonic Motility, has Acidinhibitor.
In composition of the present invention, can be according to prior art processes, add pharmaceutically acceptable auxiliary material, to make pharmacyUpper acceptable peroral dosage form.
Preferred formulation comprises granule, mixture, capsule, pill, tablet, powder, electuary, oral liquid, decoction.
The application of the present composition in preparation treatment chronic gastritis medicine.
The non-toxic medicinal material of present composition Raw medicine, safe.
The preparation method of the present composition, comprises the following steps: the bighead atractylodes rhizome, the bark of official magnolia, fructus amomi, Poria cocos, Radix Glycyrrhizae, the tuber of pinellia, dryGinger, cuttlebone, blood clam, the banksia rose, Radix Codonopsis and corydalis tuber add water or alcohol extracting, filter, concentrated, add pharmaceutically conventional auxiliary material, useGalenic pharmacy routine techniques is prepared into pharmaceutical preparations composition.
Described pharmaceutically conventional auxiliary material can be: starch, sucrose, lactose, mannitol, silicon derivative, cellulose andDerivative, alginates, gelatin, polyvinylpyrrolidone, glycerine, POLYSORBATE 80, agar, calcium carbonate, calcium bicarbonate, surface-activeAgent, polyethylene glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, kaolin, talcum powder, calcium stearate, dolomol etc.
The preparation method of present composition granule also comprises: composition is converted into after corresponding granule, and mixedClose, when use, water dissolves and takes. As treat the Chinese medicine composition of chronic gastritis, the weight ratio composition of each component is: party2～4 parts of granules of ginseng, 1～3 part of white atractylodes rhizome dispensing granule, 2～3 parts of Poria cocos granules, glycyrrhiza dispensing granule 0.4～1.6Part, 0.3～1 part of tuber of pinellia granule, 0.5～1 part of cuttlebone granule, 0.3～0.5 part of blood clam granule, the bark of official magnolia0.15～0.5 part of granule, 0.3～1 part of corydalis tuber granule, 0.15～0.3 part of fructus amomi granule, rhizoma zingiberis formula0.15～0.5 part of grain, 0.6～2 part of banksia rose granule. Above-mentioned 12 kinds of pharmaceutical formulation particles are mixed, when use, add 300mlDissolved in boiled water, takes at twice according to every part of 150ml.
The invention provides a kind of Chinese medicine composition of improved safe and effective treatment chronic gastritis, solve prior art Chinese medicineThe undesirable problem of compositions treatment chronic gastritis curative effect, causes containing toxic medicinal material treatment chronic gastritis in pharmaceutical compositionSafety issue, the side effect of avoiding western medicine to cause is large, and the problem of easily repeatedly showing effect, Patients with Chronic Gastritis trace elementThe problem that content is low.
Improved according to existing experimental model, prepared the chronic gastritis rat model similar to clinical pathologic characteristic,And research finds that after present composition treatment chronic gastritis rat, gastric mucosa pathological histology changes and obviously subtracts by experimentGently, stomach lining inflammation obviously alleviates, the obvious attenuation of muscular layer of mucosa thickness, and gastric acidity returns to normally, has good protectionStomach lining effect; And the present composition can be grown by external inhibition Hp, and the relevant chronic gastritis infecting for Hp has good therapeutic effect;Anti-inflammatory activity is strong, as present composition treatment chronic gastritis pharmacological basis.
Drug effect data:
1 pair of helicobacter pylori body outer suppressioning test:
Composition sample is that patent prescription decocting of the present invention boils extract obtained.
Control sample is Radix Codonopsis 15, rhizoma atractylodis macrocephalae 10, Poria cocos 10, honey-fried licorice root 5, stir-baked CORTEX MAGNOLIAE OFFICINALIS with rhizoma zingiberis recens juice 10, the banksia rose 10, fructus amomi 6, vinegar unitRecklessly 15 and the decocting that forms of rhizoma pinellinae praeparata 10 boil twice extract obtained.
Bacteriostatic test: agar dilution: helicobacter pylori is prepared into salt solution bacteria suspension with SPSS. Get respectively8 of sterilizing test tubes, by Chinese medicine stoste 1ml with sterile saline doubling dilution after (stoste, 1:2,1:4,1:8,1:16,1:32,1:64,1:128) add 9ml to contain the agar medium of 5%-10% Sheep Blood, fully mix, make it become variable concentrations(1:10,1:20,1:40,1:80,1:160,1:320,1:640,1:1280); Separately add 9ml with 1ml physiological salineIn blood agar plate, compare, after solidifying completely, sample injector is inoculated 1 μ l bacterium on flat board, cultivates 3 days for 37 DEG C. ObserveIn the highly diluted flat board of result medicine, without bacterium colony former, be the MIC of this Chinese medicine. The results are shown in Table 1.
Table 1 is to helicobacter pylori body outer suppressioning test result
"+" indicates bacteria growing; "-" represents asepsis growth.
Result shows, this invention composition MIC concentration is 3.47mg/ml, can suppress in vitro helicobacter pylori and MICBe less than control sample, show to suppress helicobacter pylori effect and be better than control group.
2 impacts on chronic gastritis model:
Get SPF level SD rat, male and female half and half, body weight 180 ~ 200g, totally 60. Be divided at random normal group, model group, three nine-day periods after the winter solsticeThe safe group of stomach, the high, medium and low dosage group of the present composition, 10 every group. Each group rat at modeling first month at interval of 5 days, theWithin two months, gavage only gave 60% ethanolic solution 2ml/ at interval of 7 days, replaced therebetween with the deoxycholic aicd sodium solution of 10mmol/LWater is arbitrarily drunk. Within three month, use respectively the deoxycholic aicd sodium solution of 40% ethanolic solution and 10mmol/L every rotation conduct in 3 daysDrinking water is arbitrarily drunk. Normal group is drunk equivalent distilled water. Test after 2 months and start, each treated animal gastric infusion, normal group is givenGive equivalent distilled water. Present composition dosage is 5 times that 9.58g/kg(is equivalent to clinical crude drug consumption), SANJIU WEITAI JIAONANG3.6g/kg. Control sample is Radix Codonopsis 15g, rhizoma atractylodis macrocephalae 10g, Poria cocos 10g, honey-fried licorice root 5g, stir-baked CORTEX MAGNOLIAE OFFICINALIS with rhizoma zingiberis recens juice 10g, banksia rose 10g, fructus amomiThe decocting of 6g, stir-baked RHIZOMA CORYDALIS with vinegar 15g and rhizoma pinellinae praeparata 10g composition boil twice extract obtained, dosage is 7.58g/kg, is equivalent to clinical5 times of crude drug consumption.
Next day after last administration, fasting be can't help water 16 hours, respectively organizes rat plexus vasculosus from socket of the eye and gets blood, and a part is centrifugal,Obtain serum, measure serum gastrin content (pg/m1) and micro-Fe, Zn, Cu, Cu/Zn content; A part is added on and containsIn the anticoagulant tube of 20ul Aprotinin and EDTA, mix, centrifugal, get supernatant and obtain plasma sample, for measuring Plasma Motilin Levels and Colonic Motility content(Pg/ml). Put to death rat, open abdomen, exposes stomach, makes pylorus ligation at stomach pylorus underpass, the full stomach of clip, and ligation is beautifully adornedDoor, cuts gastral cavity open along greater curvature, collects gastric juice and carries out hydrochloric acid in gastric juice and peptic activity of stomach mensuration.
Full stomach after embathing is fixed by 10% formalin, gets one approximately wide along every rat greater curvature from glandular stomach to pylorusThe holostrome coat of the stomach of 0.5cm, conventional dehydration, specimens paraffin embedding slices, HE dyeing. Under light microscopic, measure stomach lining inflammation journey with semiquantitative methodDegree, degree of inflammation is divided into 4 grades. 0 grade: represent gastric mucosa layer NIP; 1 grade: represent that a little is dispersed in inflammatory cell to gastric mucosa layer as seen;2 grades: represent the visible more inflammatory cell of gastric mucosa layer; 3 grades: represent the visible gathering of gastric mucosa layer cell infiltration in heaps.
At low power Microscopic observation holostrome stomach lining, each 10 visual field of sections observation. Divide according to the inflammation in each visual fieldProgression, by hole portion, hole body boundary, body, glandular stomach and 4 positions of glandular stomach intersection, gets its mean value and compares, and reflects with thisElimination and the inhibitory action of medicine to inflammation. Measure gastric mucosa thickness with micrometer, muscular layer of mucosa thickness, taking μ m as measuring listPosition, 8 visuals field are got in each section. Each 4 of hole portion, body. Ask respectively the mean value of hole portion, body.
Table 2 is on gastric acidity and pepsic impact
| Group | Dosage | Number of animals (only) | Free acidity (mmol/L) | Pepsin (u/ml) |
| Normal group | — | 10 | 5.24±1.50 | 29.90±14.08 |
| Model group | — | 10 | 3.06±1.29△△ | 41.43±10.41△△ |
| Sanjiu weitai capsules group | 3.6g/kg | 10 | 4.58±1.11** | 41.15±11.12** 6 --> |
| Present composition group | 9.58g/kg | 10 | 4.72±1.17** | 26.17±10.83** |
| Control sample group | 7.58g/kg | 10 | 3.97±1.25* | 37.55±9.47 |
With control group comparison:△P<0.05，△△P < 0.01; With model group comparison:*P<0.05，**P<0.01
The impact of table 3 on gastrin and motilin content
| Group | Dosage | Number of animals (only) | Serum gastrin content (pg/ml) | Motilin content |
| Normal group | — | 10 | 66.78±7.17 | 133.24±8.24 |
| Model group | — | 10 | 81.11±9.17△△ | 167.12±7.13△△ |
| Sanjiu weitai capsules group | 3.6g/kg | 10 | 71.50±12.12* | 144.89±5.12** |
| Present composition group | 9.58g/kg | 10 | 68.6±10.71** | 139.23±8.69** |
| Control sample group | 7.58g/kg | 10 | 73.12±9.8* | 155.22±11.35 |
With control group comparison:△P<0.05，△△P < 0.01; With model group comparison:*P<0.05，**P<0.01
Found that model group rat gastric juice free acidity obviously reduces, gastric juice pepsin activity obviously raises, serumGastrin content and Plasma Motilin Levels and Colonic Motility content significantly increase, and have statistical significance (p < 0.01) with Normal group comparing difference.After this composition treatment, rat gastric juice free acidity all significantly raises, rat gastric juice pepsin activity, serum gastrin content,Plasma Motilin Levels and Colonic Motility content significantly reduces. This pharmaceutical composition of result display reminding can improve the above-mentioned gastric juice composition of rat model andThe ANOMALOUS VARIATIONS degree of serum gastrin and Plasma Motilin Levels and Colonic Motility, has Acidinhibitor. The present composition and control sample groupCompare, improve the ANOMALOUS VARIATIONS degree effect of the above-mentioned gastric juice composition of rat model and serum gastrin and Plasma Motilin Levels and Colonic Motility moreGood.
The impact of table 4 on Fe, Zn, Cu, Cu/Zn content in rat blood serum
| Group | Dosage | Fe(μg/ml) | Zn(μg/ml) | Cu(μg/ml) | Cu/Zn |
| Normal group | — | 131.22±19.37 | 138.46±23.76 | 134.37±27.49 | 0.98±0.18 |
| Model group | — | 108.25±21.35△△ | 101.83±9.43△△ | 132.42±23.48 | 1.31±0.21△△ |
| Present composition group | 9.58g/kg | 126.58±17.12** | 137.17±20.18** | 131.28±26.54 | 0.96±0.15** |
| Control sample group | 7.58g/kg | 118.32±12.13* | 117.57±18.27* | 133.11±16.25 | 1.02±0.26** |
With control group comparison:△P<0.05，△△P < 0.01; With model group comparison:*P<0.05，**P<0.01
Experimental result shows, in chronic gastritis rat model blood, Fe, Zn content obviously reduce, and Cu/Zn value raises. Iron unitThe shortage of element will make gastric epithelial tissue can not get repairing, and cause atrophic gastritis; Also affect energetic supersession, causeGastrointestinal peristalsis is slowed down, and causes gastritis. Zinc has stronger local antibiosis, can promote the regeneration of mucous membrane, reduces inflammation, and alleviatesSymptom. The present composition can raise Fe in chronic gastritis rat model blood, Zn content, have significant difference (p < 0.05,P < 0.01); And more remarkable than control sample group effect.
(2) gastric mucosa pathological histology is observed:
2.1 visually observe:
Rats in normal control group gastric mucosa pinkiness, surfacing is smooth, and holostrome coat of the stomach is thicker, and coat of the stomach flesh tension force isBy force. The gastric mucosa color of model group rat is more shallow, and surface is with loose tongue shape thing, and mucous membrane is thinner, and coat of the stomach flesh tension force is poor. ThisBright composition treatment group gastric mucosa of rat is kermesinus, have with a small amount of tongue shape thing.
2.2 om observations:
Under light Normal group mirror, have no gastric epithelial cell paramophia, tunica propria is without oedema, and body of stomach is without obviouslyCell infiltration, visible a small amount of lymphocyte in the tunica propria of glandular stomach and glandular stomach intersection, part stomach hole portion, hole body interface existThe lymphocyte that mucous membrane bottom is dispersed in as seen on a small quantity. Model group stomach hole portion, hole body interface, body, glandular stomach and glandular stomach intersectionThe degree of inflammation of tunica propria is comparatively serious, in animal body of stomach tunica propria, has more lymphocyte and neutrophilic infiltration,The obvious thickening of the equal compared with normal control group of flesh layer thickness of stomach hole portion mucosal thickness, hole portion and body. The present composition and three nine-day periods after the winter solsticeStomach hole portion, body of stomach, hole body interface, the glandular stomach of the safe treated animal of stomach all alleviate than model group with glandular stomach intersection inflammation, hole portionRelatively there is attenuation trend with the mucosal thickness of body and flesh layer thickness and model group. The results are shown in Table 5,6.
The each position of the gastric mucosa degree of inflammation comparison after treatment of table 5 rat
| Group | Number of animals | Stomach hole | Hole body has a common boundary | Body of stomach | Glandular stomach and glandular stomach have a common boundary |
| Normal group | 10 | 0.10±0.01 | 0.06±0.09 | 0.16±0.05 | 0.01±0.00 |
| Model group | 10 | 1.38±0.13△△ | 0.86±0.17△ | 1.27±0.05△ | 0.85±0.14△△ |
| Sanjiu weitai capsules group | 10 | 0.45±0.08** | 0.44±0.16* | 0.30±0.11** | 0.30±0.09* |
| Present composition group | 10 | 0.31±0.11** | 0.39±0.11* | 0.41±0.12** | 0.10±0.06** |
| Control sample group | 10 | 0.61±0.05* | 0.55±0.11 | 0.59±0.04* | 0.36±0.12 |
With control group comparison:△P<0.05，△△P < 0.01; With model group comparison:*P<0.05，**P<0.01
The variation of table 6 rat lamina muscularis mucosae gastris thickness after treatment
With control group comparison:△P<0.05，△△P < 0.01; With model group comparison:*P<0.05，**P<0.01
Research finds that stomach hole, gastric body mucosa layer degree of inflammation are very apparently higher than Normal group, its mucomembranous gland layer
Thickness and muscular layer of mucosa thickness ratio obviously diminish, and point out its mucomembranous gland layer atrophy attenuation. The present compositionTreatment obviously alleviates Antrum, gastric body mucosa layer inflammation, and hole, body body of gland layer obviously thicken, and show the present compositionStomach lining inflammation to experimental chronic gastritis rat and atrophy of gastric mucosa pathology have obvious therapeutic action, have the stomach of reparation glutinousThe effect of membrane damage, and effect is better than control sample group.
3 anti-inflammatory experiments:
84 of the male ICR mouses of body weight 23～25g, adaptability is raised 3 days, is divided at random 8 groups, 12 every group. RespectivelyFor blank group, model control group, chemical drug positive controls ((aspirin 0.25/kg), Chinese patent drug positive controls (three nine-day periods after the winter solstice stomachSafe particle), high, normal, basic three dosed administration groups 19.17,9.58,5.75g/kg(is equivalent to respectively 10 of clinical crude drug consumption,5,3 times). Each treated animal respectively gavage gives each tested medicine 20ml/kg body weight, and blank group and model group give distilled water, everyDay once, totally 7 days. 1h after last administration, is coated with dimethylbenzene 0.05mL on each group of mouse right ear two sides, and left ear compares, inGive 45min after dimethylbenzene, put to death mouse, cut ears along auricle baseline, lay ears auricle with 0.8cm card punch, weigh,The difference of two auricle weight is swelling. Carry out statistical procedures with t inspection, relatively the significance degree of group difference. The results are shown in Table 7.
Swelling=auris dextra auricle weight-left ear auricle weight
Table 7 anti-inflammatory experimental result
| Group | Dosage | Number of animals (only) | Ear swelling degree (mg) |
| Normal group | — | 10 | 10.6±1.2 |
| Aspirin group | — | 10 | 5.2±1.9*** |
| Sanjiu weitai capsules group | 3.6g/kg | 10 | 7.1±1.8** |
| Present composition group | 9.58g/kg | 10 | 6.9±1.3** |
| Control sample composition | 7.58g/kg | 10 | 7.8±2.1* |
With control group comparison:*P<0.05，**P<0.01，***P<0.001
The ear swelling degree of the each dosage group of the present composition is all significantly less than Normal group, shows that this medicine is to twoMouse ear acute inflammation swelling due to toluene has antiinflammatory action, and antiphlogistic effects is suitable with control sample composition.
4 anxious poison experiments:
(1150g/kg, 575g/kg, 287.5g/kg crude drug amount, be equivalent to quantity to high, normal, basic three the dosage groups of rat600 times, 300 times, 150 times) with control group administration, every day percutaneous drug delivery, continuous 4 weeks, animal diet followed, two just, movable, bodyWeight, fur, breathing, the state of mind etc. are all without abnormal, the each dosage group of administration hematology, blood parameters, organ coefficient etc.Detect index and all belong to normally, there was no significant difference compared with control group; Pathologic finding test group pluck and histoorgan are equalHave no pathological change, have no the toxic and side effect of long-term prescription. The present composition is safe and effective.
Detailed description of the invention
Embodiment 1, the Chinese medicine composition for the treatment of chronic gastritis, the weight ratio composition of each component is: 10 parts of Radix Codonopsis, the bighead atractylodes rhizome 5Part, 10 parts, Poria cocos, 2 parts, Radix Glycyrrhizae, 3 parts of the tuber of pinellia, 5 parts of cuttlebones, 9 parts of blood clams, 3 parts of the barks of official magnolia, 3 parts of corydalis tubers, 3 parts of fructus amomis, dry3 parts of ginger, 3 parts of the banksia rose. Common above-mentioned raw materials medicine decocting is made to decoction.
Embodiment 2, the Chinese medicine composition for the treatment of chronic gastritis, the weight ratio composition of each component is: 20 parts of Radix Codonopsis, the bighead atractylodes rhizome 12Part, 15 parts, Poria cocos, 8 parts, Radix Glycyrrhizae, 9 parts of the tuber of pinellia, 10 parts of cuttlebones, 15 parts of blood clams, 10 parts of the barks of official magnolia, 10 parts of corydalis tubers, fructus amomi 6Part, 10 parts of rhizoma zingiberis, 10 parts of the banksia rose. The bighead atractylodes rhizome, the bark of official magnolia, fructus amomi, Poria cocos, Radix Glycyrrhizae, the tuber of pinellia, rhizoma zingiberis, cuttlebone, blood clam add decoctingBoil, concentrated; After the banksia rose, Radix Codonopsis and corydalis tuber adopt alcohol extract concentrated, decocting liquid and alcohol extract are merged, after vacuum drying, systemBecome powder, add appropriate amount of starch, granulate, incapsulate, obtain capsule.
Embodiment 3, the Chinese medicine composition for the treatment of chronic gastritis, the weight ratio composition of each component is: 10 parts of Radix Codonopsis, the bighead atractylodes rhizome 12Part, 15 parts, Poria cocos, 2 parts, Radix Glycyrrhizae, 9 parts of the tuber of pinellia, 5 parts of cuttlebones, 9 parts of blood clams, 10 parts of the barks of official magnolia, 10 parts of corydalis tubers, 3 parts of fructus amomis,3 parts of rhizoma zingiberis, 3 parts of the banksia rose. Above-mentioned raw material, according to weight grind into powder, are mixed and make powder, pill.
Embodiment 4, the Chinese medicine composition for the treatment of chronic gastritis, the weight ratio composition of each component is: 20 parts of Radix Codonopsis, the bighead atractylodes rhizome 5Part, 10 parts, Poria cocos, 2 parts, Radix Glycyrrhizae, 9 parts of the tuber of pinellia, 10 parts of cuttlebones, 9 parts of blood clams, 10 parts of the barks of official magnolia, 10 parts of corydalis tubers, 6 parts of fructus amomis,10 parts of rhizoma zingiberis, 10 parts of the banksia rose. The bighead atractylodes rhizome, the bark of official magnolia, fructus amomi, the banksia rose, Radix Codonopsis, Poria cocos, Radix Glycyrrhizae, corydalis tuber, the tuber of pinellia, rhizoma zingiberis, cuttlebone, wattStupefied sub-boiling, concentrated, after alcohol precipitation, get supernatant, concentrated, alcohol hypostasis is added to appropriate amount of starch, granulate, be pressed into tablet.
Embodiment 5, the Chinese medicine composition for the treatment of chronic gastritis, the weight ratio composition of each component is: 15 parts of Radix Codonopsis, the bighead atractylodes rhizome 10Part, 10 parts, Poria cocos, 6 parts, Radix Glycyrrhizae, 9 parts of the tuber of pinellia, 10 parts of cuttlebones, 10 parts of blood clams, 10 parts of the barks of official magnolia, 10 parts of corydalis tubers, fructus amomi 6Part, 9 parts of rhizoma zingiberis, 10 parts of the banksia rose. The bighead atractylodes rhizome, the bark of official magnolia, fructus amomi, Poria cocos, Radix Glycyrrhizae, the tuber of pinellia, rhizoma zingiberis, cuttlebone, blood clam, the banksia rose, partyGinseng and corydalis tuber boiling, thickening filtration; Add appropriate Sodium Benzoate and sucrose, mix, adding distil water, filling, sterilizing, obtains mouthTake liquid or mixture.
Embodiment 6, the Chinese medicine composition for the treatment of chronic gastritis, the weight ratio composition of each component is: 15 parts of Radix Codonopsis, the bighead atractylodes rhizome 9Part, 13 parts, Poria cocos, 5 parts, Radix Glycyrrhizae, 6 parts of the tuber of pinellia, 8 parts of cuttlebones, 12 parts of blood clams, 6 parts of the barks of official magnolia, 6 parts of corydalis tubers, 5 parts of fructus amomis, dry7 parts of ginger, 5 parts of the banksia rose. The banksia rose, the bighead atractylodes rhizome, the bark of official magnolia, fructus amomi, Radix Codonopsis, Poria cocos, Radix Glycyrrhizae, corydalis tuber, the tuber of pinellia, rhizoma zingiberis, cuttlebone, blood clamBoiling, concentrated, dry, add appropriate Steviosin and mix, granulate, dry, obtain granule.
Embodiment 7, the Chinese medicine composition for the treatment of chronic gastritis, substantially the same manner as Example 6, but the weight ratio group of each componentCheng Shi: 15 parts of Radix Codonopsis, 10 parts of the bighead atractylodes rhizomes, 10 parts, Poria cocos, 6 parts, Radix Glycyrrhizae, 9 parts of the tuber of pinellia, 10 parts of cuttlebones, 10 parts of blood clams, the bark of official magnolia 10Part, 10 parts of corydalis tubers, 6 parts of fructus amomis, 9 parts of rhizoma zingiberis, 10 parts of the banksia rose.
Embodiment 8, the Chinese medicine composition for the treatment of chronic gastritis, the weight ratio composition of each component is: Radix Codonopsis granule 2～4 parts, 1～3 part of white atractylodes rhizome dispensing granule, 2～3 parts of Poria cocos granules, 0.4～1.6 part of glycyrrhiza dispensing granule, tuber of pinellia granule0.3～1 part, 0.5～1 part of cuttlebone granule, 0.3～0.5 part of blood clam granule, bark of official magnolia granule 0.15～0.5 part, 0.3～1 part of corydalis tuber granule, 0.15～0.3 part of fructus amomi granule, 0.15～0.5 part of rhizoma zingiberis granule,0.6～2 part of banksia rose granule. Above-mentioned 12 kinds of pharmaceutical formulation particles are mixed, when use, add 300ml dissolved in boiled water, according toEvery part of 150ml takes at twice.
Claims (5)
1. a Chinese medicine composition for the treatment of chronic gastritis, is characterized in that, the weight portion of bulk drug is composed as follows: Radix Codonopsis 10～20
Part, 5～12 parts of the bighead atractylodes rhizomes, 10～15 parts, Poria cocos, 2～8 parts, Radix Glycyrrhizae, 3～9 parts of the tuber of pinellia, 5～10 parts of cuttlebones, blood clam 9～15 parts, 3～10 parts of the barks of official magnolia, 3～10 parts of corydalis tubers, 3～6 parts of fructus amomis, 3～10 parts of rhizoma zingiberis, 3～10 parts of the banksia rose;
In this composition, add pharmaceutically acceptable auxiliary material, make pharmaceutically acceptable peroral dosage form;
Described oral formulations: include but not limited to granule, mixture, capsule, pill, tablet, decoction.
2. the Chinese medicine composition for the treatment of chronic gastritis according to claim 1, is characterized in that, the weight of described each bulk drugAmount part consists of: 15 parts of Radix Codonopsis, 10 parts of the bighead atractylodes rhizomes, 10 parts, Poria cocos, 6 parts, Radix Glycyrrhizae, 9 parts of the tuber of pinellia, 10 parts of cuttlebones, 10 parts of blood clams,10 parts of the barks of official magnolia, 10 parts of corydalis tubers, 6 parts of fructus amomis, 9 parts of rhizoma zingiberis, 10 parts of the banksia rose.
3. the Chinese medicine composition of the treatment chronic gastritis described in claim 1 or 2 is in the medicine of preparation treatment chronic gastritisApplication.
4. treat a preparation method for the Chinese medicine composition of chronic gastritis, bulk drug is: 10～20 parts of Radix Codonopsis, the bighead atractylodes rhizome 5～12Part, 10～15 parts, Poria cocos, 2～8 parts, Radix Glycyrrhizae, 3～9 parts of the tuber of pinellia, 5～10 parts of cuttlebones, 9～15 parts of blood clams, the bark of official magnolia 3～10Part, 3～10 parts of corydalis tubers, 3～6 parts of fructus amomis, 3～10 parts of rhizoma zingiberis, 3～10 parts of the banksia rose, is characterized in that, comprises the following steps:The bighead atractylodes rhizome, the bark of official magnolia, fructus amomi, Poria cocos, Radix Glycyrrhizae, the tuber of pinellia, rhizoma zingiberis, cuttlebone, blood clam, the banksia rose, Radix Codonopsis and corydalis tuber add water or alcohol extractingGet, filter, concentrated, add pharmaceutically conventional auxiliary material, be prepared into pharmaceutical preparations composition with galenic pharmacy routine techniques.
5. the preparation method of the Chinese medicine composition for the treatment of chronic gastritis according to claim 4, is characterized in that, granulePreparation method be: be converted into corresponding granule amount according to crude drug amount, prepare respectively pharmaceutical formulation particle, by above-mentioned 12 kindsPharmaceutical formulation particle mixes, and adds 300ml dissolved in boiled water when use, takes at twice according to every part of 150ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310742427.4A CN103751739B (en) | 2013-12-30 | 2013-12-30 | The Chinese medicine composition for the treatment of chronic gastritis, its application in the medicine of preparation treatment chronic gastritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310742427.4A CN103751739B (en) | 2013-12-30 | 2013-12-30 | The Chinese medicine composition for the treatment of chronic gastritis, its application in the medicine of preparation treatment chronic gastritis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103751739A CN103751739A (en) | 2014-04-30 |
| CN103751739B true CN103751739B (en) | 2016-05-11 |
Family
ID=50519166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310742427.4A Expired - Fee Related CN103751739B (en) | 2013-12-30 | 2013-12-30 | The Chinese medicine composition for the treatment of chronic gastritis, its application in the medicine of preparation treatment chronic gastritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103751739B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104013895A (en) * | 2014-05-20 | 2014-09-03 | 柳晖 | Traditional Chinese medicine composition for treating epigastric pain caused by duodenal ulcer |
| CN105267864A (en) * | 2015-10-16 | 2016-01-27 | 施君平 | Traditional Chinese medicine preparation for treating chronic gastritis and method for preparing traditional Chinese medicine preparation |
| CN105920557B (en) * | 2016-05-31 | 2021-02-02 | 普洱市民族传统医药研究所 | Changlingweishu tablet and its preparation process |
| CN107335039A (en) * | 2017-07-24 | 2017-11-10 | 甘肃瀛海堂医药有限公司 | A kind of Chinese medicine composition for treating deficient cold type gastritis, gastric ulcer |
| CN108310302B (en) * | 2018-03-27 | 2023-09-19 | 江阴市中医院 | Pharmaceutical composition for treating chronic gastritis |
| CN111773359A (en) * | 2019-04-06 | 2020-10-16 | 梁允晖 | A capsule for treating gastritis |
| CN112168936A (en) * | 2020-10-28 | 2021-01-05 | 贵州克艾康医药开发有限公司 | Compound Chinese herbal medicine capsule for treating and killing helicobacter pylori and preparation method thereof |
| CN114129684B (en) * | 2021-10-29 | 2023-02-10 | 合肥创新医药技术有限公司 | Traditional Chinese medicine composition and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323599A (en) * | 2000-05-12 | 2001-11-28 | 王绍彬 | Medicine for treating diseases of digestive system |
| CN102430104A (en) * | 2011-12-13 | 2012-05-02 | 荣成市科学技术情报研究所 | Traditional Chinese medicine composite for treating epigastric pain |
-
2013
- 2013-12-30 CN CN201310742427.4A patent/CN103751739B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323599A (en) * | 2000-05-12 | 2001-11-28 | 王绍彬 | Medicine for treating diseases of digestive system |
| CN102430104A (en) * | 2011-12-13 | 2012-05-02 | 荣成市科学技术情报研究所 | Traditional Chinese medicine composite for treating epigastric pain |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103751739A (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751739B (en) | The Chinese medicine composition for the treatment of chronic gastritis, its application in the medicine of preparation treatment chronic gastritis and preparation method thereof | |
| CN102451268B (en) | Traditional Chinese medicine preparation for treating helicobacter pylori related gastropathy and preparation method | |
| CN100364594C (en) | Medicine for treating chronic superficial gastritis and peptic ulcer diseases | |
| CN101584810B (en) | Medicine composition for treating gastritis and peptic ulcer and preparation method thereof | |
| CN102614260A (en) | Medicine for treating gastric ulcer and duodenal ulcer and preparing method and application thereof | |
| CN105535511A (en) | Stomach harmonizing and pain relieving granule and preparation method thereof | |
| CN102139080B (en) | Chinese medicinal composition for treating chronic gastritis and peptic ulcer and preparation method thereof | |
| CN101342282A (en) | Chinese medicinal composition for treating gastropathy and preparation method | |
| CN103479824B (en) | A kind ofly treat Chinese medicine composition of chronic periodontitis and gastritis and preparation method thereof | |
| CN113209194A (en) | Composition for treating chronic gastritis and preparation method and application thereof | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN111939217A (en) | Traditional Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN105213780B (en) | A kind of Chinese medicine composition that treating chronic gastritis and its application | |
| CN112156162B (en) | Medicine for protecting gastric mucosa and preparation method thereof | |
| CN103735631B (en) | A kind of pharmaceutical composition for the treatment of hepatitis B and preparation method thereof | |
| CN103585206A (en) | Preparation method of Chrysosplenium extract and its application | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN107519261A (en) | A kind of Chinese medicine composition for treating leukaemia and preparation method thereof | |
| CN103432502B (en) | A kind of Chinese patent medicine for the treatment of peptic ulcer disease | |
| CN103301309B (en) | Traditional Chinese herbal medicine for treating laryngocarcinoma and esophagus cancer | |
| CN114796432B (en) | Traditional Chinese medicine composition for treating gastritis and preparation method thereof | |
| CN106563095A (en) | Compound preparation for dental ulcer, and preparation method of compound preparation | |
| CN105168847A (en) | Traditional Chinese medicine for treating helicobacter pylori infected peptic ulcer | |
| CN105435099A (en) | Traditional Chinese medicine for treating superficial gastritis caused by damp heat in spleen and stomach | |
| CN105561143A (en) | Pharmaceutical composition for treating chronic gastritis and chronic cholecystitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160511 Termination date: 20201230 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |